MILBEMAX chewable tablets for dogs

Quốc gia: Ai-len

Ngôn ngữ: Tiếng Anh

Nguồn: HPRA (Health Products Regulatory Authority)

Thành phần hoạt chất:

Milbemycin oxime; Praziquantel

Sẵn có từ:

Elanco GmbH

Mã ATC:

QP54AB51

INN (Tên quốc tế):

Milbemycin oxime; Praziquantel

Liều dùng:

12.5, 125.0 mg/tablet

Dạng dược phẩm:

Chewable tablet

Loại thuốc theo toa:

POM: Prescription Only Medicine as defined in relevant national legislation

Khu trị liệu:

milbemycin oxime, combinations

Tình trạng ủy quyền:

Authorised

Ngày ủy quyền:

2016-04-22

Đặc tính sản phẩm

1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Milbemax 12.5 mg/125 mg chewable tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCES:
Milbemycin oxime
12.5 mg
Praziquantel
125.0 mg
EXCIPIENTS:
QUALITATIVE
COMPOSITION OF EXCIPIENTS AND
OTHER CONSTITUENTS
QUANTITATIVE
COMPOSITION
IF THAT INFORMATION
IS ESSENTIAL
FOR PROPER ADMINISTRATION OF THE
VETERINARY MEDICINAL PRODUC
t
_ _
Propylene glycol (E 1520)
4.54 mg
Iron oxide, brown (E 172)
3.29 mg
Butylhydroxyanisole (E 320)
1.32 mg
Propyl gallate (E 310)
0.46 mg
Glycerol (E422)
Starch, pregelatinised
Natural chicken flavour
Confectioner’s sugar NF
Water, purified
Sodium chloride
Citric acid monohydrate
Oval shaped, dark brown chewable tablet.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Dogs (≥ 5kg).
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
For dogs with, or at risk from mixed infections of cestodes,
gastrointestinal nematodes, eyeworm,
lungworms and/or heartworm. This veterinary medicinal product is only
indicated when use against
cestodes and nematodes or prevention of heartworm
disease/angiostrongylosis is indicated at the same
time.
Cestodes:
Treatment of
_ _
tapeworms:
_Dipylidium caninum, Taenia _
spp
_., Echinococcus _
spp
_., Mesocestoides _
spp
_. _
_ _
Gastrointestinal Nematodes
Treatment of:
Hookworm:
_Ancylostoma caninum, _
Roundworms:
_ Toxocara canis, Toxascaris leonina, _
Whipworm:
_ Trichuris vulpis_
.
_ _
Eyeworm
Treatment of
_Thelazia callipaeda_
(see specific treatment schedule under section 3.9 “Administration
routes and dosage”).
_ _
_ _
Lungworms
Treatment of:
_Angiostrongylus vasorum_
(Reduction of the level of infection by immature adult (L5) and adult
parasite
stages; see specific treatment and prevention disease schedules under
section 3.9 “Administration routes
and dosage”),
_Crenosoma vulpis_
(Reduction of the level of infection).
_ _
Heartworm
Prevention of heartworm disease (
_Dirofilaria immitis_
) if concomitant treatment against cestodes is
indicated.
3.3
CONTRAINDICATIONS